AU2010280368B2 - Novel proteins - Google Patents

Novel proteins Download PDF

Info

Publication number
AU2010280368B2
AU2010280368B2 AU2010280368A AU2010280368A AU2010280368B2 AU 2010280368 B2 AU2010280368 B2 AU 2010280368B2 AU 2010280368 A AU2010280368 A AU 2010280368A AU 2010280368 A AU2010280368 A AU 2010280368A AU 2010280368 B2 AU2010280368 B2 AU 2010280368B2
Authority
AU
Australia
Prior art keywords
seq
prt5
antibody
prt7
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010280368A
Other languages
English (en)
Other versions
AU2010280368A1 (en
Inventor
Orly Devary
Tamara Sandler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Two To Biotech Ltd
Original Assignee
Two To Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Two To Biotech Ltd filed Critical Two To Biotech Ltd
Publication of AU2010280368A1 publication Critical patent/AU2010280368A1/en
Application granted granted Critical
Publication of AU2010280368B2 publication Critical patent/AU2010280368B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
AU2010280368A 2009-08-02 2010-08-02 Novel proteins Ceased AU2010280368B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL200202A IL200202A0 (en) 2009-08-02 2009-08-02 Novel proteins
IL200202 2009-08-02
PCT/IL2010/000621 WO2011016026A2 (en) 2009-08-02 2010-08-02 Novel proteins

Publications (2)

Publication Number Publication Date
AU2010280368A1 AU2010280368A1 (en) 2012-03-15
AU2010280368B2 true AU2010280368B2 (en) 2015-07-23

Family

ID=42263570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010280368A Ceased AU2010280368B2 (en) 2009-08-02 2010-08-02 Novel proteins

Country Status (11)

Country Link
US (1) US8647632B2 (enExample)
EP (2) EP2461829B1 (enExample)
JP (3) JP2013500739A (enExample)
KR (1) KR101623355B1 (enExample)
CN (1) CN102596247B (enExample)
AU (1) AU2010280368B2 (enExample)
CA (1) CA2769001C (enExample)
IL (3) IL200202A0 (enExample)
IN (1) IN2012DN00879A (enExample)
SG (2) SG178097A1 (enExample)
WO (1) WO2011016026A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742061A4 (en) * 2011-08-08 2015-05-27 Two To Biotech Ltd NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND USES THEREOF IN METHODS FOR THE TREATMENT OF METABOLIC, CARDIAC AND IMMUNE DISORDERS
CN105916874A (zh) * 2014-01-02 2016-08-31 两合生物科技有限公司 新型多肽
CN104262468B (zh) * 2014-09-28 2017-01-18 新乡医学院 一种葡萄糖转运蛋白抑制多肽及其制备方法、应用
TWI604888B (zh) 2015-03-05 2017-11-11 積水特殊化學美國有限責任公司 用於氯乙烯單體（ｖｃｍ）聚合之聚乙烯醇（ｐｖｏｈ）分散劑
KR102713301B1 (ko) 2015-12-11 2024-10-02 고쿠리츠다이가쿠호진 고치다이가쿠 췌장암 및 췌장관 내 유두상 점액성 종양의 마커

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073303A2 (en) * 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5286846A (en) 1991-06-14 1994-02-15 The Government Of The United States Of America As Represented By The Dept. Of Health And Human Services Amino acid derivative and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
AU2001261513A1 (en) * 2000-05-15 2001-11-26 Braswell, Glenn A. Composition and method for increasing testosterone levels
US6566333B2 (en) 2000-06-19 2003-05-20 Uab Research Foundation Osteoclast secreted chemokine and uses thereof
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
WO2006042002A2 (en) 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20080248134A1 (en) 2005-05-04 2008-10-09 Auckland Uniservices Limited Oral compositions, use and combinations of N-[2-(dimethylamino)ethyl]-2,6 dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide and closely related analogues thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073303A2 (en) * 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAN, W. et al, "Molecular Cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity", Biochemical Journal, Vol 357, 2001, pages 127-135. *
HARIHARAN, N. et al, "Expression of Human Hepatic Glucokinase in Transgenic Mice Liver Results in Decreased Glucose Levels and Reduced Body Weight", Diabetes, Vol 46, 1997, Pages 11-16. *

Also Published As

Publication number Publication date
AU2010280368A1 (en) 2012-03-15
IL240134A0 (en) 2015-09-24
EP2461829B1 (en) 2016-01-06
JP2013500739A (ja) 2013-01-10
EP2985035A1 (en) 2016-02-17
HK1171672A1 (zh) 2013-04-05
CN102596247A (zh) 2012-07-18
IN2012DN00879A (enExample) 2015-07-10
SG10201404735VA (en) 2014-10-30
US20120121602A1 (en) 2012-05-17
IL200202A0 (en) 2010-05-31
JP5833780B2 (ja) 2015-12-16
IL217758A0 (en) 2012-03-29
CA2769001A1 (en) 2011-02-10
CN102596247B (zh) 2014-08-06
WO2011016026A3 (en) 2011-05-26
EP2461829A2 (en) 2012-06-13
KR20120063474A (ko) 2012-06-15
IL217758A (en) 2015-10-29
KR101623355B1 (ko) 2016-05-23
SG178097A1 (en) 2012-03-29
EP2461829A4 (en) 2013-06-19
CA2769001C (en) 2016-07-26
US8647632B2 (en) 2014-02-11
WO2011016026A2 (en) 2011-02-10
JP2015212302A (ja) 2015-11-26
IL240134A (en) 2016-07-31
JP2015157811A (ja) 2015-09-03

Similar Documents

Publication Publication Date Title
JP6502851B2 (ja) 炎症性状態の予防、処置、および診断のための方法および化合物
JP2006523085A (ja) アセチル化タンパク質
US20190271705A1 (en) Sh2 domain variants
US8647632B2 (en) Proteins
TW201333202A (zh) 澱粉球蛋白（ａｍｙｌｏｓｐｈｅｒｏｉｄ）所結合而誘發成熟神經細胞死亡之標靶分子、抑制澱粉球蛋白所誘導之神經細胞死亡的方法及物質、及其等之用途
US7034118B2 (en) Corticotropin-releasing factor2 receptors
US20210347824A1 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
US7534580B2 (en) PSP94 diagnostic reagents and assays
CN102300583A (zh) Goodpasture抗原结合蛋白及其检测
CN101282989A (zh) 用于诊断风湿性疾病的方法
US9296786B2 (en) Shortened secreted polypeptides
EP1499725A1 (en) Psp94 binding protein and psp94 diagnostic assays
KR102202082B1 (ko) 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
JP2003530109A (ja) エルビンをコードする遺伝子及びその診断及び治療的使用
HK1171672B (en) Novel proteins
JPH07503141A (ja) 新規抗▲ｒｂ▼モノクローナル抗体の特性
JP2001508297A (ja) ヒトエンドスルフィン遺伝子
JP2002101877A (ja) モノクローナル抗体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired